Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Gilead Inks Deal With Carna Biosciences For Immuno-Oncology

By Zacks Investment ResearchStock MarketsJun 26, 2019 06:24AM ET
www.investing.com/analysis/boi-gordo-frigorificos-fora-das-compras-e-precos-estaveis-200434782
Gilead Inks Deal With Carna Biosciences For Immuno-Oncology
By Zacks Investment Research   |  Jun 26, 2019 06:24AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
GILD
-0.96%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AAPL
-2.70%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AGEN
+1.29%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GSK
-2.50%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NVO
-1.54%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Gilead Sciences, Inc. (NASDAQ:GILD) entered a research and development collaboration with Japan-based biopharmaceutical company, Carna Biosciences Inc.

Both the companies have collaborated to develop and commercialize small molecule compounds in immuno-oncology.

The deal will also allow Gilead to access Carna’s proprietary lipid kinase drug discovery platform. Per the terms, the company will license worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target from Carna.

In exchange, Carna will receive an upfront payment of $20 million and is eligible to receive up to an additional $450 million in milestone payments. Carna will also receive royalties on future net sales.

Gilead is currently making efforts to build a pipeline in immuno-oncology. In December 2018, it collaborated with Agenus (NASDAQ:AGEN) for the development and commercialization of up to five novel immuno-oncology therapies.

Gilead’s stock has gained 9.5% in the year so far compared with the industry's growth of 4.2%.

Recently, the company collaborated with San Francisco-based Nurix Therapeutics, Inc. to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.

Earlier, Gilead also collaborated with Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases.

Given the persistent decline in HCV sales, stiff competition from the likes of Glaxo (NYSE:GSK) and pricing pressure in the HIV market, the company is looking to newer avenues to boost the top line. Gilead has made quite a few collaborations, of late, to strengthen and diversify its pipeline.

The company is intending to foray into the inflammation market with late-stage candidate, filgotinib. It has collaborated with big pharma companies like Novo Nordisk (NYSE:NVO) to develop treatments for non-alcoholic steatohepatitis (NASH).

Zacks Rank

Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>




GlaxoSmithKline plc (GSK): Free Stock Analysis Report

Novo Nordisk A/S (NVO): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Agenus Inc. (AGEN): Free Stock Analysis Report

Original post

Zacks Investment Research

Gilead Inks Deal With Carna Biosciences For Immuno-Oncology
 

Related Articles

Gilead Inks Deal With Carna Biosciences For Immuno-Oncology

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email